Should I buy or sell Immunovant stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMVT shares. View IMVT analyst ratings or view top-rated stocks .

What is Immunovant's stock price target for 2024?

13 brokers have issued 1-year price targets for Immunovant's stock. Their IMVT share price targets range from $21.00 to $57.00. On average, they predict the company's stock price to reach $42.62 in the next year. This suggests a possible upside of 5.3% from the stock's current price. View analysts price targets for IMVT or view top-rated stocks among Wall Street analysts .

How have IMVT shares performed in 2023?

Immunovant's stock was trading at $17.75 on January 1st, 2023. Since then, IMVT stock has increased by 127.9% and is now trading at $40.46. View the best growth stocks for 2023 here .

Are investors shorting Immunovant?

Immunovant saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 7,060,000 shares, an increase of 5.5% from the October 31st total of 6,690,000 shares. Based on an average daily volume of 2,150,000 shares, the short-interest ratio is currently 3.3 days. Currently, 11.6% of the shares of the stock are sold short. View Immunovant's Short Interest .

When is Immunovant's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 2nd 2024. View our IMVT earnings forecast .

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.45).

What ETFs hold Immunovant's stock?

ETFs with the largest weight of Immunovant (NASDAQ:IMVT) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) , Alpha Architect U.S. Quantitative Momentum ETF (QMOM) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Principal Healthcare Innovators ETF (BTEC) . IQ Chaikin U.S. Small Cap ETF (CSML) .

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Walt Disney (DIS) , Fulcrum Therapeutics (FULC) , Myovant Sciences (MYOV) , Alibaba Group (BABA) , Inovio Pharmaceuticals (INO) , JD.com (JD) and Johnson & Johnson (JNJ) .

Who are Immunovant's major shareholders?

Immunovant's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (5.36%), Alpine Global Management LLC (0.87%), Fred Alger Management LLC (0.82%), Avidity Partners Management LP (0.81%), Redmile Group LLC (0.76%) and Armistice Capital LLC (0.72%). Insiders that own company stock include Atul Pande , Douglas J Hughes , Eva Renee Barnett , Frank Torti , George V Migausky , Julia G Butchko , Mark S Levine , Peter Salzmann , Sciences Ltd Roivant and William L Macias . View institutional ownership trends .

How do I buy shares of Immunovant?

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated Most-Upgraded StocksMost-Upgraded

Immunovant Stock Price, News & Analysis (NASDAQ:IMVT)

$40.40

-0.41 (-1.00%)

(As of 01:57 PM ET)

Compare

Today's Range: $39.75
▼
$40.84
50-Day Range: $31.31
▼
$40.81
52-Week Range: $14.05
▼
$44.19

Volume: 395,031 shs
Average Volume: 1.39 million shs
Market Capitalization: $5.84 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $42.62

Immunovant MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 5.3% Upside
$42.62 Price Target
Short Interest: Bearish
11.64% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.77
Based on 10 Articles This Week
Insider Trading: Acquiring Shares
$58 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.82) to ($1.88) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

844th out of 949 stocks

Biological Products, Except Diagnostic Industry

139th out of 152 stocks

2.5

Analyst's Opinion

Consensus Rating
Immunovant has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $42.62, Immunovant has a forecasted upside of 5.3% from its current price of $40.46.
Amount of Analyst Coverage
Immunovant has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
11.64% of the float of Immunovant has been sold short.
Short Interest Ratio / Days to Cover
Immunovant has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Immunovant has recently increased by 5.53%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Immunovant does not currently pay a dividend.
Dividend Growth
Immunovant does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMVT.

3.2

News and Social Media Coverage

News Sentiment
Immunovant has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Immunovant this week, compared to 3 articles on an average week.
Search Interest
Only 9 people have searched for IMVT on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
12 people have added Immunovant to their MarketBeat watchlist in the last 30 days. This is an increase of 9% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immunovant insiders have bought 4,182.41% more of their company's stock than they have sold. Specifically, they have bought $58,000,008.00 in company stock and sold $1,354,378.00 in company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Immunovant is held by insiders.
Percentage Held by Institutions
42.45% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Immunovant are expected to decrease in the coming year, from ($1.82) to ($1.88) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immunovant is -20.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immunovant is -20.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immunovant has a P/B Ratio of 14.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Immunovant Stock (NASDAQ:IMVT)

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

IMVT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMVT Stock News Headlines

December 4, 2023 | americanbankingnews.com

Immunovant, Inc. (NASDAQ:IMVT) Short Interest Update

December 3, 2023 | americanbankingnews.com

UBS Group Raises Immunovant (NASDAQ:IMVT) Price Target to $56.00

December 5, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.

December 1, 2023 | markets.businessinsider.com

Analyst Ratings for Immunovant

December 1, 2023 | finance.yahoo.com

Here’s Why Immunovant (IMVT) Outperformed in Q3

November 29, 2023 | markets.businessinsider.com

Immunovant’s IMVT-1402 Shows Promising Phase 1 Results and Market Opportunity Following Competitor’s Trial Failure

November 28, 2023 | markets.businessinsider.com

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

November 28, 2023 | markets.businessinsider.com

Immunovant Announces Positive Initial Data From Phase 1 Study Of IMVT-1402

December 5, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

November 26, 2023 | americanbankingnews.com

Julia G. Butchko Sells 3,265 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock

November 26, 2023 | americanbankingnews.com

Eva Renee Barnett Sells 4,055 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock

November 26, 2023 | americanbankingnews.com

Peter Salzmann Sells 16,217 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock

November 26, 2023 | americanbankingnews.com

Immunovant, Inc. (NASDAQ:IMVT) CEO Sells $531,593.26 in Stock

November 25, 2023 | finance.yahoo.com

Immunovant Inc CEO Peter Salzmann Sells Over 16,000 Shares

November 18, 2023 | markets.businessinsider.com

Promising Prospects of Immunovant’s Clinical Trials Driving Growth Potential

November 15, 2023 | markets.businessinsider.com

Where Immunovant Stands With Analysts

November 14, 2023 | finance.yahoo.com

Immunovant, Inc.'s (NASDAQ:IMVT) Intrinsic Value Is Potentially 60% Above Its Share Price

November 14, 2023 | seekingalpha.com

Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena

November 13, 2023 | finance.yahoo.com

Immunovant to Present at Upcoming Investor Conferences

November 10, 2023 | finance.yahoo.com

Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus

November 9, 2023 | finance.yahoo.com

Immunovant Inc (IMVT) Reports Fiscal Q2 Results: R&D Investments Surge Amidst Clinical Progress

November 9, 2023 | benzinga.com

Recap: Immunovant Q2 Earnings

November 9, 2023 | finance.yahoo.com

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

November 1, 2023 | msn.com

Immunovant (IMVT) Price Target Increased by 19.11% to 48.41

October 28, 2023 | finance.yahoo.com

Insider Sell: Chief Legal Officer Mark Levine Sells 4,107 Shares of Immunovant Inc

October 26, 2023 | finanznachrichten.de

HanAll Biopharma Reports Third Quarter 2023 Financial Results and Provides a Business Update

October 25, 2023 | msn.com

Piper Sandler Maintains Immunovant (IMVT) Overweight Recommendation

See More Headlines

Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/05/2023
Next Earnings (Estimated): 2/02/2024
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IMVT
CUSIP: N/A
CIK: 1764013
Web: www.immunovant.com
Phone: 917-580-3099
Fax: N/A
Employees: 164
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $42.62
High Stock Price Target: $57.00
Low Stock Price Target: $21.00
Potential Upside/Downside: +4.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-210,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -73.07%
Return on Assets: -64.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.23
Quick Ratio: 7.23

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.78 per share
Price / Book: 14.68

Miscellaneous

Outstanding Shares: 144,662,000
Free Float: 137,718,000
Market Cap: $5.90 billion
Optionable: Not Optionable
Beta: 0.70

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Frank M. Torti M.B.A. (Age 44)
M.D., Executive Chairperson of the Board
Comp: $92.5k
Dr. Peter Salzmann M.B.A. (Age 55)
M.D., CEO & Director
Comp: $1.02M
Ms. Eva Renee Barnett M.B.A. (Age 43)
Chief Financial Officer
Comp: $871.07k
Dr. William L. Macias M.D. (Age 65)
Ph.D., Chief Medical Officer
Comp: $719.88k
Dr. Jay S. Stout Ph.D. (Age 60)
Chief Technology Officer
Dr. Chau Cheng M.B.A.
Ph.D., Vice President of Investor Relations
Mr. Mark S. Levine (Age 50)
Chief Legal Officer & Corporate Secretary
Ms. Lauren Schrier M.B.A.
Vice President of Marketing
Ms. Christine Blodgett
Vice President of Human Resources
Dr. Julia G. Butchko Ph.D. (Age 52)
Chief Development Officer
Comp: $531k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IMVT Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunovant stock right now?: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMVT shares.
View IMVT analyst ratings or view top-rated stocks.
What is Immunovant's stock price target for 2024?: 13 brokers have issued 1-year price targets for Immunovant's stock. Their IMVT share price targets range from $21.00 to $57.00. On average, they predict the company's stock price to reach $42.62 in the next year. This suggests a possible upside of 5.3% from the stock's current price.
View analysts price targets for IMVT or view top-rated stocks among Wall Street analysts.
How have IMVT shares performed in 2023?: Immunovant's stock was trading at $17.75 on January 1st, 2023. Since then, IMVT stock has increased by 127.9% and is now trading at $40.46.
View the best growth stocks for 2023 here.
Are investors shorting Immunovant?: Immunovant saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 7,060,000 shares, an increase of 5.5% from the October 31st total of 6,690,000 shares. Based on an average daily volume of 2,150,000 shares, the short-interest ratio is currently 3.3 days. Currently, 11.6% of the shares of the stock are sold short.
View Immunovant's Short Interest.
When is Immunovant's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, February 2nd 2024.
View our IMVT earnings forecast.
How were Immunovant's earnings last quarter?: Immunovant, Inc. (NASDAQ:IMVT) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.45).

What ETFs hold Immunovant's stock?: ETFs with the largest weight of Immunovant (NASDAQ:IMVT) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Principal Healthcare Innovators ETF (BTEC).IQ Chaikin U.S. Small Cap ETF (CSML).
What other stocks do shareholders of Immunovant own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).
Who are Immunovant's major shareholders?: Immunovant's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (5.36%), Alpine Global Management LLC (0.87%), Fred Alger Management LLC (0.82%), Avidity Partners Management LP (0.81%), Redmile Group LLC (0.76%) and Armistice Capital LLC (0.72%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias.
View institutional ownership trends.
How do I buy shares of Immunovant?: Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IMVT) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Immunovant Stock Price, News & Analysis (NASDAQ:IMVT)

Immunovant MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Immunovant Stock (NASDAQ:IMVT)

IMVT Stock Price History

IMVT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IMVT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™